Dr. Thomas Urbig joined the industry in 2001 as leader of the downstream and analytical groups at Micromet and held various positions with increasing responsibility at the Process Development department. Later he became Vice President of Process Sciences and Head of Manufacturing for Micromet overseeing everything from early process development to operational oversight. In 2012 Micromet became part of Amgen where Thomas is leading now Process Sciences at Amgen’s R&D hub in Munich. Currently his focus is on early development of Amgen’s bispecific antibody constructs. For these new modalities Thomas is responsible for Molecule Assessment, early Drug Substance, and Drug Product development. Thomas is a trained chemist and received his PhD from the Philipps University of Marburg. Follwing his PhD he spent several years as an Alexander von Humbold fellow at the Harvard University followed by an extended stay at the Biochemistry Department of the University of Stockholm. Alltogether he has now more than 25 years experience in the expression, purification, and characterization of proteins.